CD10 and CK7 Are Not Necessary to Confirm Hepatic Origin of Adenocarcinoma
When a liver biopsy shows adenocarcinoma, CD10 and CK7 should be ordered as part of a comprehensive immunohistochemical panel, but they are used to differentiate between primary liver tumors and metastases—not to confirm hepatic origin. In fact, the diagnostic approach depends entirely on whether you're trying to distinguish hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), or metastatic disease.
The Critical Distinction: What Are You Actually Trying to Diagnose?
The question contains a fundamental misconception. Adenocarcinoma in the liver is not typically of hepatocellular origin—it's either:
- Cholangiocarcinoma (primary biliary adenocarcinoma)
- Metastatic adenocarcinoma from another organ
True hepatocellular carcinoma is not an adenocarcinoma; it's a hepatocellular malignancy with different markers entirely.
The Recommended Immunohistochemical Approach
For Differentiating Cholangiocarcinoma from Metastases
The 2024 French Association for the Study of the Liver (AFEF) guidelines provide the definitive panel 1:
Primary recommended panel (GRADE 1+):
- CK7
- CK20
- CDX2/SATB2 (for GI origin)
- TTF1 (for lung origin)
- GATA3 (for breast origin in women)
Secondary marker (GRADE 2+):
- C-reactive protein (CRP) antibodies—highly specific (88-91%) and sensitive (76-93%, up to 97% for small-duct CCA) for distinguishing CCA from metastases 1
The classic CCA phenotype is: CK7+ / CK20− / CRP+ with negative site-specific transcription factors 1.
When Chronic Liver Disease Is Present
If there's underlying cirrhosis or chronic liver disease, the differential becomes more complex—distinguishing between:
- Cholangiocarcinoma
- Poorly differentiated HCC
- Scirrhous HCC (which can be CK7+/CK19+)
In this scenario, you need hepatocellular and canalicular markers 1:
Hepatocellular markers:
- HepPar-1
- Glypican-3
- Arginase-1
- Alpha-fetoprotein
Canalicular markers (including CD10):
- CD10 (canalicular pattern)
- Polyclonal CEA (pCEA)
- BSEP
The 2025 EASL guidelines note that CD10, pCEA, and BSEP have higher specificity and sensitivity for HCC diagnosis compared to HepPar-1 and glypican-3 2.
Specific Role of CD10
CD10 is a canalicular marker used to identify hepatocellular differentiation, not to confirm "liver origin" of adenocarcinoma 1.
- Canalicular CD10 staining (88% sensitivity, 100% specificity) supports HCC diagnosis 3, 4
- CD10 is not useful for diagnosing cholangiocarcinoma
- CD10 helps distinguish HCC from metastatic adenocarcinoma when the differential is unclear
Specific Role of CK7
CK7 is part of the basic phenotyping panel but is NOT specific for liver origin:
- CK7 is positive in cholangiocarcinoma (part of the CK7+/CK20− phenotype) 1
- CK7 is typically negative in HCC (<5% of cases are CK7+) 1
- CK7 is positive in many metastatic adenocarcinomas (breast, lung, ovarian, pancreatic) 5
- CK7 alone cannot determine liver origin—it must be interpreted with other markers
The Algorithmic Approach
Step 1: Assess Clinical Context
- Is there underlying chronic liver disease/cirrhosis?
- Is there a known primary malignancy elsewhere?
- What does imaging show?
Step 2: Initial Immunohistochemical Panel
For adenocarcinoma without known primary:
- CK7, CK20, CDX2/SATB2, TTF1, GATA3 (in women) 1
Step 3: Interpret Results
- CK7+/CK20−/CRP+ with negative site-specific markers → Cholangiocarcinoma
- CK7+/CK20+ or other patterns → Consider metastatic disease with appropriate site-specific workup
- If chronic liver disease present and morphology unclear → Add hepatocellular markers (HepPar-1, Arginase-1, CD10, pCEA, glypican-3) 1
Step 4: Additional Tissue Sampling
The guidelines strongly recommend obtaining non-tumoral liver tissue (GRADE 2+) 1:
- Presence of cirrhosis/fibrosis completely changes the differential diagnosis
- Essential for distinguishing early HCC from dysplastic nodules
- Helps guide surgical planning
Critical Pitfalls to Avoid
- Don't assume adenocarcinoma = hepatocellular origin—it almost never is
- Don't order CD10 alone—it requires interpretation within a panel and clinical context
- Don't exhaust the biopsy sample—preserve tissue for molecular analysis 1
- Don't skip non-tumoral liver biopsy—it's essential for accurate diagnosis 1
- Unusual profiles exist: 5-20% of HCC can be CK7+/CK19+; <10% of CCA can be HepPar1+ or glypican-3+ 1
When Doubt Persists
If immunohistochemistry doesn't resolve the diagnosis, pursue additional workup 1:
- Digestive endoscopy
- FDG-PET scan
- Search for extrahepatic primary tumor
- Multidisciplinary tumor board discussion